Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Male breast cancer: a disease distinct from female breast cancer.

Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F.

Breast Cancer Res Treat. 2018 Sep 28. doi: 10.1007/s10549-018-4921-9. [Epub ahead of print] Review.

PMID:
30267249
2.

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.

Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND.

Clin Cancer Res. 2018 Nov 1;24(21):5225-5232. doi: 10.1158/1078-0432.CCR-18-0564. Epub 2018 Jul 16.

PMID:
30012563
3.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 May 9. doi: 10.1007/s10549-018-4813-z. [Epub ahead of print]

PMID:
29744674
4.

Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.

Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK.

Horm Cancer. 2018 Apr;9(2):82-94. doi: 10.1007/s12672-017-0314-5. Epub 2018 Jan 16. Review.

PMID:
29340907
5.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

6.

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.

Rafferty SW, Eisner JR, Moore WR, Schotzinger RJ, Hoekstra WJ.

Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. doi: 10.1016/j.bmcl.2014.04.024. Epub 2014 Apr 16.

PMID:
24775307
7.

Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys.

Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW.

Trends Endocrinol Metab. 1998 Feb;9(2):62-7.

PMID:
18406243
8.

Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome.

Bruns CM, Baum ST, Colman RJ, Dumesic DA, Eisner JR, Jensen MD, Whigham LD, Abbott DH.

Int J Obes (Lond). 2007 Oct;31(10):1579-85. Epub 2007 May 1.

9.

Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys.

Bruns CM, Baum ST, Colman RJ, Eisner JR, Kemnitz JW, Weindruch R, Abbott DH.

J Clin Endocrinol Metab. 2004 Dec;89(12):6218-23.

PMID:
15579780
10.

Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation.

Eisner JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH.

Obes Res. 2003 Feb;11(2):279-86.

11.

Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess.

Eisner JR, Barnett MA, Dumesic DA, Abbott DH.

Fertil Steril. 2002 Jan;77(1):167-72.

PMID:
11779609
12.

Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys.

Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH.

J Clin Endocrinol Metab. 2000 Mar;85(3):1206-10.

PMID:
10720063
13.

Insulin action during variable hyperglycemic-hyperinsulinemic infusions in hyperandrogenic anovulatory patients and healthy women.

Dumesic DA, Nielsen MF, Abbott DH, Eisner JR, Nair KS, Rizza RA.

Fertil Steril. 1999 Sep;72(3):458-66.

PMID:
10519617
14.

Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women.

Dumesic DA, Abbott DH, Eisner JR, Herrmann RR, Reed JE, Welch TJ, Jensen MD.

Fertil Steril. 1998 Jul;70(1):94-101.

PMID:
9660428
15.
16.

Supplemental Content

Loading ...
Support Center